CTLA4 and hepatocellular carcinoma: Combining multiple immune checkpoint blockade therapies is a strategy to increase responders, but among HCC patients, only 33% responded to treatment with anti-CTLA4 and anti-PD1 antibodies (12), which is a regimen that places patients at increased risk for life-threatening autoimmune reactions (89).